•
Jun 30, 2023

Glaukos Q2 2023 Earnings Report

Glaukos's Q2 2023 financial results were announced, featuring record net sales and double-digit topline growth.

Key Takeaways

Glaukos reported Q2 2023 net sales of $80.4 million, an 11% increase year-over-year, with a gross margin of approximately 75% and a non-GAAP gross margin of approximately 82%. The company raised its 2023 net sales guidance to $304 million to $308 million.

Net sales reached $80.4 million, marking an 11% increase year-over-year.

Glaucoma net sales were $61.9 million, up 10% year-over-year.

Corneal Health net sales increased by 11% to $18.5 million.

Gross margin was approximately 75%, with a non-GAAP gross margin of about 82%.

Total Revenue
$80.4M
Previous year: $72.7M
+10.6%
EPS
-$0.55
Previous year: -$0.83
-33.7%
Gross margin
75%
Previous year: 75%
+0.0%
Non-GAAP gross margin
82%
Previous year: 83%
-1.2%
SG&A expenses
$53.1M
Previous year: $49.9M
+6.4%
Gross Profit
$60.3M
Previous year: $54.9M
+9.9%
Cash and Equivalents
$94.8M
Previous year: $103M
-7.5%
Free Cash Flow
-$13.9M
Previous year: -$21.6M
-35.5%
Total Assets
$957M
Previous year: $1.03B
-7.2%

Glaukos

Glaukos

Glaukos Revenue by Segment

Forward Guidance

The company expects 2023 net sales to be in the range of $304 million to $308 million based on the latest foreign currency exchange rates.

Revenue & Expenses

Visualization of income flow from segment revenue to net income